Michael Link, MD, professor of pediatrics, Stanford Cancer Institute, 2018 Giant of Cancer Care in Pediatrics, discusses the evolution of treatment in pediatric cancer.
Michael Link, MD
Advertisement
Articles by Michael Link, MD
Michael Link, MD, professor, Pediatrics, Stanford Cancer Institute, and a 2018 Giant of Cancer Care in Pediatric Oncology discusses the current paradigm for treatment in pediatric cancer.
Michael Link, MD, Lydia J. Lee Professor in Pediatric Cancer, professor, Pediatrics, Stanford Cancer Institute, and a 2018 Giant of Cancer Care in Pediatric Oncology, discusses the randomized trial testing nelarabine in patients with T-cell malignancies.
Advertisement
Latest Updated Articles
Dr. Link on Nelarabine in Newly Diagnosed T-Cell MalignanciesPublished: July 10th 2018 | Updated:
Dr. Link on the Current State of Treatment For Pediatric CancerPublished: October 8th 2018 | Updated:
Dr. Link on Evolution of Treatment in Pediatric CancerPublished: November 22nd 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5